1Kim H J, Choi Y, Min W S, et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia [J]. Transplantation ,2007 ( 4 ) : 1082-1091.
2Nishida T, Akatsuka Y, Morishima Y, et al. Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2AI, ACC-I , in patients receiving HLA genotypically matched unrelated bone marrow transplant [J]. Br J Haematol, 2004,124 ( 5 ) : 629 -635.
4Giorgini A, Noble A. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4 ^+ CD25 ^+ Foxp3 ^+ regulatory T cells in nonlymphopenic hosts [J]. J Leukoc Biol, 2007,82 ( 5 ) : 1053-1061.
5Jung U, Foley J E, Erdmann A A, et al. Ex vivo rapamycin generates Thl/Tcl or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to posttransplant rapamycin therapy [ J ]. Biol Blood Marrow Trans- plant, 2006,12 ( 9 ) : 905-918.
6Simpson D. New developments in the prophylaxis and treatment of graft versus host disease[ J ]. Expert Opin Pharmacother,2001,2(7) :1109-1117.
7Creamer D, Martyn-Simmons C L, Osborne G,et al. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy [J]. Arch Dermato1,2007,143 ( 9 ) : 1157-1162.
8Endimiani A,Paterson D L. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases[J]. Semin Respir Crit Care Med, 2007,28 (6) :646-655.
9Jones R N, Sader H S, Fritsche T R,et al. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem [J]. Diagn Microbiol Infect Dis, 2007,59 ( 4 ) : 467 -472.
10Huang Y T,Liao C H ,Teng L J, et al. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan [ J ]. Clin Microbiol Infect, 2008,14 ( 2 ) : 124-129.
二级参考文献5
1Holler E, Kolb HJ, Moller A,et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood,1990,75:1011-1016.
2Lawrence JA, Karen MK. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene relevance to disease. J Leuk Biol,1999, 66:562-566.
3Deeg HJ, Storb R. Graft-versus-host disease:pathophysiological and clinical aspects. Ann Rev Med,1984, 35:11-24.
4Kroeger KM, Carville KS, Abraham LJ,et al. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol,1997, 34:391-399.
5Chen CJ,Yen JH,Tsai WC, et al. The TNF2 allele does not contribute towards susceptibility to systemic lupus erythematosus.Immunol,1997,Lett 55:1-3.
10Couban S,Simpson DR,Barnett MJ,et al.A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.Blood.2002;100(5):1525-1531.
